RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

25 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

06 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22 Feb 2024 07:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

07 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

31 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

12 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

04 Jan 2024 06:58:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

15 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023

13 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

25 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

17 Oct 2023 16:01:00 By Nasdaq GlobeNewswire